PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
5 hedge funds and large institutions have $15.6K invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 34 closing their positions.
87% less funds holding
Funds holding: 38 → 5 (-33)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 34
100% less capital invested
Capital invested by funds: $3.89M → $15.6K (-$3.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$5.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.17M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$768K |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$479K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$406K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$318K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Stifel Financial
St. Louis,
Missouri
| – | -$2K | -13,721 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$2K | -10,603 | Closed |
|
28
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -3,825 | Closed |
|
|
HI
29
Harbour Investments
Madison,
Wisconsin
| – | -$2K | -3,600 | Closed |
|
|
TWC
30
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$211 | -850 | Closed |
|
31
BNP Paribas Financial Markets
Paris,
France
| – | -$14 | -79 | Closed |
|
PHAS Hedge Fund Activity: Q4 2022 in Review
5 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2022, worth a combined $15.6K — down 100% from $3.89M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of PHAS and 1 opened new positions — a net loss of 33 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Hamilton Lane Advisors, opening a new position worth an estimated $5.61K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.17M sold.
- 5 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $15.6K of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
- 1 fund opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 34 closed out, a net change of -33 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Hamilton Lane Advisors, an estimated $5.61K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was NEA Management Company, an estimated $1.17M sold.
Based on aggregated 13F filings for Q4 2022.